Vir Biotechnology (VIR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.47
- Estimate
- $0.73
- Surprise
- -35.2%
- Revenue (period 2026-06-30)
- $238.9M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Vir Biotechnology (VIR) missed the $0.73 estimate with diluted EPS of $0.47 — a large 35.2% shortfall.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VIR Sell at 5.6/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -35.2% surprise compares with a -82.1% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Counterparty: PRO-XTEN platform license (Sanofi/Amunix)
- Quality below floor (3.4 < 4.0)
- Value-trap signals (3/5): Margin compression (op margin -81.6%), High leverage (D/E 1.7), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.40
- Price target
- $18.08
- Stop
- $10.59
- Upside to target
- +58.6%
- Reward-to-risk
- 3.9:1
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
VIR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.93B
- P/E (fwd)
- -4.6
- 52-week range
- $4.75–$11.94
- Off 52-week high
- 4.5%
- RSI (14)
- 72
- Volume vs avg
- 0.62×
- Score today
- 5.6/10